Clinical Trial Update: Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating capecitabine for recurrent ovarian epithelial cancer or primary peritoneal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Capecitabine (capecitabine)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: TERMINATED